DTOC is a shell company. The stock to buy for huge gains is NVNO. It's breaking out.
20M people in the US suffer with swollen legs because pooled blood isn't pumped back to the heart. So, the market is huge. The P2 trial had stellar results (pain, swelling and ulcers were significantly reduced). The pivotal P3 trial will be completed before year end. There's no competition in this space. Considering the size of the market, the valuation can easily reach a $billion, $2 billion.... = $100, $200 ... per share.
NVNO developed the VenoValve to remedy that. It's the Holy Grail of venous stasis. It will be huge! $Digital Transformation Opportunities Corp(DTOC)$ $enVVeno Medical Corp.(NVNO)$
Human heart with veins and arteries
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
